Chinese Journal of Dermatology ›› 2026, e20240491.doi: 10.35541/cjd.20240491

• Reviews • Previous Articles     Next Articles

The value of immune-targeted therapy for disease modification in atopic dermatitis

Zhang Li1, Xu Ruisi1, Wan Zhilei1, Wu Qingyi1, Ke Jincheng2, Zhang Yuqing1, Hao Yonghong3, Zhou Qiongyan4, Gao Xinghua1   

  1. 1Department of Dermatology, the First Hospital of China Medical University, Shenyang 110001, China; 2Department of Dermatology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen 361021, China; 3Department of Dermatology, Chinese PLA General Hospital, Beijing 100853, China; 4Department of Dermatology, the First Affiliated Hospital of Ningbo University, Ningbo 315010, China
  • Received:2024-09-12 Revised:2025-10-29 Online:2026-02-09 Published:2026-06-24
  • Contact: Gao Xinghua E-mail:gaobarry@hotmail.com
  • Supported by:
    National Key R&D Program of China(2023YFC2508200)

Abstract: 【Abstract】 Atopic dermatitis (AD) is a chronic inflammatory skin disease in which antigen presentation and T-cell activation, the persistence of memory T cells, and subclinical chronic inflammation are closely associated with disease chronicity, recurrence, and the development of atopic comorbidities. Disease modification aims to alter the natural course of a disease through clinical intervention and to achieve sustained deep remission after treatment discontinuation. In recent years, the introduction of multiple targeted biologic agents has markedly changed the clinical manifestations of AD, as well as its natural disease course and associated comorbidities. This article reviews recent advances in biologic targeted therapies for AD and their disease-modifying value.

Key words: Dermatitis, atopic, Chronic inflammation, Disease modification, Molecular targeted therapy, Immunologically activated cell